BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19124804)

  • 1. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
    Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
    J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia.
    Del Giudice I; Morilla A; Osuji N; Matutes E; Morilla R; Burford A; Maravelaki S; Owusu-Ankomah K; Swansbury J; A'Hern R; Brito-Babapulle V; Catovsky D
    Cancer; 2005 Nov; 104(10):2124-32. PubMed ID: 16211545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
    Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach.
    Passam F; Tachynopoulou V; Skoumi D; Tsompanakou A; Stavropoulos-Giokas A; Vadikolia C; Anagnostopoulos A; Paterakis G
    Ann Hematol; 2006 Nov; 85(11):795-805. PubMed ID: 16871389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
    D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L
    Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
    Sheikholeslami MR; Jilani I; Keating M; Uyeji J; Chen K; Kantarjian H; O'Brien S; Giles F; Albitar M
    Cytometry B Clin Cytom; 2006 Jul; 70(4):270-5. PubMed ID: 16906585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
    Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
    Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia.
    Mainou-Fowler T; Porteous A; Nicolle A; Proctor SJ; Anderson JJ; Summerfield G
    Int J Oncol; 2008 Jul; 33(1):169-74. PubMed ID: 18575763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
    Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
    Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
    Abousamra NK; El-Din MS; Azmy E
    Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.
    Morabito F; Cutrona G; Gentile M; Matis S; Todoerti K; Colombo M; Sonaglio C; Fabris S; Reverberi D; Megna M; Spriano M; Lucia E; Rossi E; Callea V; Mazzone C; Festini G; Zupo S; Molica S; Neri A; Ferrarini M
    Br J Haematol; 2009 Jun; 146(1):44-53. PubMed ID: 19438486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
    Molica S; Digiesi G; Mirabelli R; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Morabito F; Neri A; Baldini L; Ferrarini M
    Eur J Haematol; 2009 Sep; 83(3):208-14. PubMed ID: 19459926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
    Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Marini R; Cox MC; Panetta P; Suppo G; Degan M; Bruno A; Gattei V; Amadori S
    Haematologica; 2004 Dec; 89(12):1468-75. PubMed ID: 15590397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.
    Francis S; Karanth M; Pratt G; Starczynski J; Hooper L; Fegan C; Pepper C; Valcarcel D; Milligan DW; Delgado J
    Cancer; 2006 Sep; 107(5):1023-33. PubMed ID: 16862572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.
    Pratt G; Harding S; Holder R; Fegan C; Pepper C; Oscier D; Gardiner A; Bradwell AR; Mead G
    Br J Haematol; 2009 Jan; 144(2):217-22. PubMed ID: 19016722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.